Skip to main content

Table 2 Clinical characteristics of study participants during MDR-TB treatment at St.Peter’s Specialized Hospital and ALERT center, Addis Ababa, Ethiopia

From: Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study

Clinical characteristics N(%)
Case registration New case 77 (8.3)
Relapse 124 (13.3)
After failure of first treatment 213 (22.9)
After failure of re-treatment 442 (47.5)
Treatment after being lost to follow- up 4 (0.4)
Transfer -in 2 (0.2)
Other 11 (1.2)
TB treatment in the past Yes 788 (84.6)
No 63 (6.8)
Unknown 27 (2.9)
Treatment taken for past TB First-line drugs 792 (85.1)
Second- line drugs 25 (2.7)
Both first and second line drugs 4 (0.4)
Second- line past injectable treatment Kanamycin 1 (0.1)
Amikacin 6 (0.6)
Capreomycin 17 (1.8)
Streptomycin 33 (3.5)
Anatomical site TB Pulmonary 817 (87.8)
Extrapulmonary 59 (6.3)
MTB detection Bacteriologically confirmed MDR-TB 850 (91.3)
Clinically diagnosed MDR-TB 27 (2.9)
NA 2 (0.2)
MTB confirmation GeneXpert MTB/RIF positive 347 (37.5)
Culture 234 (25.1)
Line probe assay 214 (23.0)
Sputum smear positive 29 (3.1)
Resistance /Sensitivity testing GeneXpert MTB/RIF 356 (38.2)
Line probe assay 232 (24.9)
Phenotypic drug susceptibility testing 242 (26.0)
NA + other 42 (4.7)
HIV status HIV positive MDR-TB patients 171 (18.4)
HIV negative MDR-TB patients 685 (73.6)
HIV status unknown MDR-TB patients 23 (2.4)
Pattern of resistance Isoniazid and rifampicin resistance 341 (40.1)
GeneXpertMTB/RIF rifampicin only resistance 260 (30.6)
Rifampicin resistance with isoniazid susceptibility 38 (4.5)
Isoniazid, rifampicin, ethambutol, streptomycin, resistance 132 (15.5)
Isoniazid, rifampicin and streptomycin resistance 1 (0.1)
Others 94 (10.1)